Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

Schaapveld, M (2015), NEJM (Link to abstract)

The authors report the relative risk of second cancer after treatment for Hodgkin Lymphoma (HL) to be significantly higher than in the general population, particularly for solid tumors. The standardized incidence ratio (SIR) was 4.6 in the study cohort as compared with the general population and remained elevated 35 years after treatment completion. Even though treatment toxicity was reduced over the last decades, the risk of a second malignancy remains largely unchanged. Results showed a small reduction in hematologic malignancies.


*  The risk of second solid cancers did not change within the last 20 years despite reduction of toxicity and more restricted radiation fields.